

(51) International Patent Classification<sup>6</sup> :

A61K 38/17, 9/00, 9/16

A.

(43) International Publication Date: 8 February 1996 (08.02.96)

(21) International Application Number: PCT/GB95/01735

(22) International Filing Date: 24 July 1995 (24.07.95)

(30) Priority Data:

9414966.3

26 July 1994 (26.07.94)

GB

(71) Applicant (for all designated States except US): DANBIOSYST  
UK LIMITED [GB/GB]; Albert Einstein Centre, Highfields  
Science Park, Nottingham NG7 2TN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WATTS, Peter [GB/GB];  
Flat 2, 47 Highfield Road, West Bridgford, Nottingham  
NG2 6DR (GB). ILLUM, Lisbeth [DK/GB]; 19 Cavendish  
Crescent North, The Park, Nottingham NG7 1BA (GB).(74) Agent: BASSETT, Richard; Eric Potter Clarkson, St. Mary's  
Court, St. Mary's Gate, Nottingham NG1 1LE (GB).(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH,  
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE,  
KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN,  
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT,  
BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD,  
SZ, UG).

Published

With international search report.

(54) Title: DRUG DELIVERY COMPOSITION FOR THE NASAL ADMINISTRATION OF ANTIVIRAL AGENTS

## (57) Abstract

A drug delivery composition for nasal administration is provided which comprises the antiviral agent ICAM-1 and a bioadhesive material. The bioadhesive material may be a chitosan solution, a liquid formulation comprising a polymeric material or a plurality of bioadhesive microspheres. The polymeric material is preferably gellan gum or alginate. The microspheres may comprise starch, chitosan, hyaluronic acid, or gelatin.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DRUG DELIVERY COMPOSITION FOR THE  
NASAL ADMINISTRATION OF ANTIVIRAL AGENTS

The present invention relates to compositions for nasal administration and,  
5 more particularly, to compositions for nasal administration of the antiviral agent known as Intercellular Adhesion Molecule 1 (ICAM-1).

Viral infections affecting the nasal cavity such as influenza and rhinoviral infections can be not only unpleasant disease conditions in normal  
10 individuals, but in certain "at risk" groups represent a serious threat to health.

A variety of agents are now available that can be considered as a possible mode of treatment. These include low molecular weight antiviral agents  
15 such as Enviroxine, Pirodavir as well as antiviral proteins such as interferon-alpha and sialidase inhibitors (see for example Von Itzstein *et al.* Nature. 363 418, 1993). More recently it has been shown that rhinoviruses attach to tissue via a specific adhesion process and consequently the binding of virus can be prevented using a cell adhesion  
20 molecule such as ICAM-1 or its fragments. (Martin *et al.*, A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection, Nature 344, 1990, 70-72).

While such antiviral materials can be shown to be effective *in vitro* using  
25 appropriate tests on virus inhibition or binding blockage, it is found that such systems are not effective *in vivo* for example using the nasal route of administration or have to be given in high and frequent doses that can given rise to toxic effects (Hayden *et al.* New Eng. J. Med. 314 71 (1986)) or could be disadvantageous on cost grounds. (Al-Nakib, W. *et al.* Antimicrobial Agents and Chemotherapy 33, 522 (1989)).  
30

Therefore, it would be a significant advantage if it was found possible to increase the effectiveness of antiviral compounds in the nasal cavity. Various nasal delivery systems have previously been described. The nasal administration of starch microspheres has been described by Illum in  
5 various patents or patent applications. In US 4847091 she described how the low molecular weight drug, sodium cromoglycate, could be complexed to the surface of DEAE-dextran microspheres in order to increase residence time in the nose. PCT/GB88/00836, PCT/GB90/101676 describe how microspheres can be used to increase the systemic uptake of  
10 poorly transported molecules such as peptides and proteins.

The use of Chitosan as a bioadhesive material to improve the absorption of polar drugs from the nasal cavity and across other mucosal surfaces has been described by Illum in Topics in Pharmaceutical Science 1991.  
15 Editors: Crommellin D.J.A. and Midha, K.K., Stuttgart, Medpharm., 1992. p 71 and in PCT/GB90/00291. Chitosan systems for local application have been described by Partain (US 4946870). He described systems that formed substantive films in contact with topical surfaces. The various examples provided by Partain are intended for application as  
20 lotions to the skin. Intranasal administration is mentioned in US 4946870 but no examples of systems that are not film forming in the nasal cavity are declared. It is also noted that in order to form coherent and substantive films the Partain examples contain high quantities of volatile material such as ethanol. This method would be precluded in the nasal  
25 application of such systems.

The use of gellan gum as an in-situ gelling material has been described in AUS 86.63189. with reference to ophthalmic applications. The drugs which could be administered by means of the ophthalmic composition  
30 according to the invention included antiviral agents such as acyclovir,

adenosine, arabinoside, interferon and interferon inducing agents. The pharmaceutical uses of gellan gums and their rheological properties have been described by Deasy *et al.* Int. J. Pharm. 73 117 (1991) and Kublik and Muller, Eu. J. Pharm. Biopharm 39 192 (1993) and Sanzgiri *et al.* J. Control. Rel. 26 195 (1993).

We have now found that the effectiveness of the antiviral agent ICAM-1 in the nasal cavity can be greatly increased by administration with a bioadhesive material.

10

The present invention therefore provides a drug delivery composition for nasal administration comprising ICAM-1 and a bioadhesive material.

We use the term "bioadhesive" to include a material that adheres to the nasal mucosa by chemical or physical binding such as Van der Waals interaction, ionic interaction, hydrogen bonding or by polymer chain entanglement. The adhesion may taken place to the epithelial (cellular) surface or to the mucus overlying that surface.

Rhinoviruses belong to the picornavirus family and cause about 50% of common colds. Most rhinoviruses share a common receptor on human cells. The glycoprotein inter cellular adhesion molecule-1 (ICAM-1) has recently been identified as the cellular receptor for the subgroup of rhinoviruses known as the major group. ICAM-1 is expressed on cells of multiple lineages at sites of inflammation. ICAM-1 is glycosylated protein with a molecular weight of 85-90 kD, the protein portion having a molecular weight of 45-50 kD.

In a first embodiment of the invention, the bioadhesive material is chitosan, preferably as a solution. The chitosan solution may be made in

water or any suitable pharmaceutically acceptable buffer system. Phosphate or lactate buffers are especially preferred.

The concentration of chitosan in the solution is preferably in the range  
5 0.01 to 50% w/v, more preferably 0.1 to 30%, more preferably 0.1% to 15% and most preferably 0.2% to 2.0%.

Chitosan is deacetylated chitin, or poly-N-acetyl-D-glucosamine. It is available from Protan Laboratories Inc, Redmond, Washington 98052 and,  
10 depending on the grade selected, can be soluble in water up to pH 6.0. A 1% solution of non-water soluble chitosan (Sea Cure) may be made by making a slurry (eg. 2g/100ml) in water and adding an equal volume of organic acid (eg 100ml of 2% acetic acid) and stirring vigorously for one hour. Water-soluble chitosan (see Cure<sup>+</sup>) may dissolve without organic  
15 or inorganic acids being present.

Chitosan has previously been used to precipitate proteinaceous material, to make surgical sutures and as an immunostimulant. It has also been employed previously in oral drug formulations in order to improve the  
20 dissolution of poorly soluble drugs (Sawayanagi *et al*, Chem. Pharm. Bull., 31, 2062-2068 (1983)) or for the sustained release of drugs (Nagai *et al*, Proc. Jt. US- Jpn. Semin. Adv. Chitin, Chitosan, Relat. Enzymes, 21-39. Zikakis J.P. (ed), Academic Press. Orlando (1984)) by a process of slow erosion from a hydrated compressed matrix.

25

The chitosan formulation may also contain a preservative such as benzalkonium chloride. The ICAM-1 is preferably mixed with the chitosan solution in concentrations in the range of 0.01% to 20% w/v, preferably 0.1% to 10% w/v, and more preferably 0.2% to 5% w/v. The  
30 Chitosan formulation can be administered using a conventional nasal spray

device familiar to those skilled in the art.

In a second embodiment of the invention, the bioadhesive material is a plurality of microspheres.

5

The microsphere can be prepared from a suitable material such as starch, starch derivatives, amylopectin, amylopectin and cross-linked variants thereof, gelatin, albumin, alginate, gellan, hyaluronic acid, chitosan, dextran and dextran derivatives. The microspheres may also comprise  
10 ion-exchange materials. By the term "derivatives" we particularly mean esters and ethers of the parent compound that can be unfunctionalised or functionalised to contain, for example, ionic groupings.

Suitable starch derivatives include hydroxyethyl starch, hydroxypropyl  
15 starch, carboxymethyl starch, cationic starch, acetylated starch, phosphorylated starch, succinate derivatives or starch and grafted starches. Such starch derivatives are well known and described in the art (for example Modified Starches: Properties and Uses, O.B. Wurzburg, CRC Press Boca Raton (1986)).

20

Suitable dextran derivatives include diethylaminoethyl-dextran (DEAE-dextran), dextran sulphate, dextran methyl-benzylamide sulphonates, dextran methyl-benzylamide carboxylates, carboxymethyl dextran, diphosphonate dextran, dextran hydrazide, palmitoyldextran and dextran  
25 phosphate. These microspheres can be prepared by emulsification procedures or by spray drying. Both are established procedures in pharmaceutical formulation and are familiar to those skilled in the art. The microspheres are preferably of a size from 1 to 200 micron, more preferably 10-100 microns, and most preferably 40-60  $\mu\text{m}$ . Substantially  
30 uniform, solid microspheres are preferred.

The drug-microsphere formulations are prepared as a freeze-dried or spray dried powder system or a physical mixture. The microspheres can be administered by a nasal insufflator or a device that would be normally used for deposition of powders into the lungs but suitably modified for  
5 nasal administration. Examples include the Ventolin inhaler (from Glaxo) and the Dura Dry Powder Device (US Patent 5327883). Bsepak device (WO935950).

The bioadhesive microspheres have the property of swelling in water.  
10 This swelling nature leads to a preferential binding to the mucosal surface of the nose thereby leading to improved retention. The degree of swelling should be such that the particle increases its diameter (as measured by a suitable technique such as the light microscope, laser diffractometer) when immersed in water by a factor of at least 1.2 times. The preferable  
15 increase in diameter is 1.5 times or greater.

The formulation can either be prepared by freeze drying from a suspension of the microspheres in drug solution or by mechanically mixing the freeze dried, spray dried or dried microspheres with the drug in a  
20 powder form. The drug can be sorbed into or onto the microspheres after their preparation. Alternatively the drug can also be incorporated into the microspheres during their production. The technique of spray drying or an emulsification technique or other techniques known to the person skilled in the art can be used to produce microspheres of the desired size  
25 that contain the drug. The conditions of preparation are selected by the person skilled in the art to provide particles that have the necessary integrity and also to maintain the biological activity of the drug. Preparation of these microsphere systems is well described in the pharmaceutical literature (see for example Davis *et al*, (Eds),  
30 "Microspheres and Drug Therapy", Elsevier Biomedical Press, 1984).



Emulsion and phase separation methods are both suitable. For example, albumin microspheres may be made using the water-in-oil emulsification method where a dispersion of albumin is produced in a suitable oil by homogenization techniques or stirring techniques, with the addition if  
5 necessary of small amounts of an appropriate surface active agent.

Emulsification techniques are also used to produce starch microspheres as described in GB 1 518 121 and EP 223 303 as well as for the preparation of microspheres of gelatin. Proteinaceous microspheres may also be  
10 prepared by coacervation methods such as simple or complex coacervation or by phase separation techniques using an appropriate solvent or electrolyte solution. Full details of the methods of preparing these systems can be obtained from standard text books (see for example Florence and Attwood, Physicochemical Principles of Pharmacy 2nd Ed., MacMillan  
15 Press, 1988, Chapter 8).

The microspheres can be hardened by well known cross-linking procedures such as heat treatment or by chemical cross-linking agents. Suitable agents include dialdehydes, including glyoxal, malondialdehyde, succinicaldehyde, adipaldehyde, glutaraldehyde and phthalaldehyde,  
20 diketones such as butadione, epichlorohydrin, polyphosphate and borate. Dialdehydes are used to cross-link proteins such as albumin by interaction with amino groups and diketones form schiff bases with amino groups. Epichlorohydrin activates compounds with nucleophiles such as amino or  
25 hydroxyl to an epoxide derivative.

For example, microspheres were made as follows:

### Starch Microspheres

15ml of 5 % starch solution (pH=7) was kept at a constant temperature of 70°C and stirred (500 rpm) while a 30% solution of PEG was added  
5 (about 7ml) until phase separation had occurred. The system was then stirred for a further 15 min, before it was cooled on ice during constant stirring. The microspheres were then isolated by filtration and freeze dried. With a stirring speed of 500 rpm, particles with a mean size of  $33 \mu\text{m} \pm 10 \mu\text{m}$  were produced.

10

### Gelatine Microspheres

30 ml of 10% bovine gelatin (pH=8.5) was kept at a constant temperature of 50°C and stirred (500 rpm) while a 30% solution of PEG was added  
15 (about 20 ml) until the coacervation region was reached. To control this step, a nephelometer can be used. The mixture was cooled on ice during constant stirring. The microspheres were isolated by filtration and freeze dried.

20 With a stirring speed of 500 rpm, particles with a mean size of  $60 \mu\text{m} \pm 10 \mu\text{m}$  were produced.

The content of ICAM-1 in the microsphere formulation is preferably in the range 0.1% to 50% w/w, more preferably 0.5% to 25% and most  
25 preferably 1% to 20% w/w.

In a third embodiment of the invention the bioadhesive material may be a liquid formulation comprising a polymeric material.

30 The polymeric material should provide a viscous solution to aid retention

in the nasal cavity. Preferably, the polymeric material will gel when in contact with the nasal mucosa either due to the rise in temperature, the presence of specific cations or change in pH.

- 5 Suitable polymeric materials include gellan gum, welan, rhamsan, alginate, carboxymethylcellulose, sodium alginate, xanthan, agar, guar derivatives such as carboxymethyl guar gum, carageenan, dextran sulphate, keratan, dermatan, pectin. Polysaccharides and derivatives are particularly suitable ("Polysaccharides and derviatives" edited by R C  
10 Whistler and J N BeMiller (3rd Ed.) Academic Press, San Diego 1993).

A preferred material is gellan gum, which is the deacetylated form of the extracellular polysaccharide from *Pseudomonas elodae*. Native/high-acyl gellan is composed of a linear sequence of tetra-saccharide repeating units  
15 containing D-glucuronopyranosyl, D-glucopyranosyl and L-rhamnopyranosyl units and acyl groups.

Another preferred material is alginate. Alginate is composed of two building blocks of monomeric units namely  $\beta$ -D-mannuronopyranosyl and  
20  $\alpha$ -guluronopyranosyl units. The ratio of D-mannuronic acid and L-guluronic acid components and their sequence predetermines the properties observed for alginates extracted from different seaweed sources.

Welan is produced by an *Alcaligenes* species. Welan has the same basic  
25 repeating unit as gellan but with a single glycosyl sidechain substituent. The side unit can be either an  $\alpha$ -L-rhamnopyranosyl or an  $\alpha$ -L-mannopyranosyl unit linked (1 $\rightarrow$ 3) to the 4-O-substituted  $\beta$ -D-glucopyranosyl unit in the backbone.

30 Rhamsan is produced by an *Alcaligenes* species. Rhamsan has the same

repeating backbone unit as that of gellan but with a disaccharide side chain on O-6 of the 3-O-substituted  $\beta$ -D-glucopyranosyl unit. The side chain is a  $\beta$ -D-glucopyranosyl-(1-6)- $\alpha$ -D-glucopyranosyl unit.

- 5 Xanthan is produced by a number of Xanthomonas strains. The polymer backbone, made up of (1 $\rightarrow$ 4)-linked  $\beta$ -D-glucopyranosyl units is identical to that of cellulose. To alternate D-glucosyl units at the 0-3 position, a trisaccharide side chain containing a D-glucuronosyl unit between two D-mannosyl units is attached. The terminal  $\beta$ -D-mannopyranosyl unit is
- 10 glycosidically linked to the 0-4 position of the  $\beta$ -D-glucopyranosyluronic acid unit, which in turn is glycosidically linked to the 0-2 position of an  $\alpha$ -D-mannopyranosyl unit.

- 15 Carrageenan is a group of linear galactan polysaccharides extracted from red seaweeds of the Gigartinaceae, Hypneaceae, Solieriaceae, Phyllophoraceae and Furcellariaceae families that have an ester sulfate content of 15-40% and contain alternatively (1 $\rightarrow$ 3)- $\alpha$ -D- and (1 $\rightarrow$ 4)- $\alpha$ -D-glycosidic linkages.

- 20 Agar is a hydrophilic colloid extracted from certain marine algae of the class Rhodophyceae where it occurs as a structural carbohydrate in the cell walls (see also Kang and Pettitt: Xanthan, Gellan, Welan and Rhamsan in Industrial gums by Whistler and BeMiller (Eds), Academic Press Inc. London, 1993).

25

- Mixtures of gellan with other polymers such as alginate can be used, gelling of the mixture being caused by the gellan gum. Other combinations of gums can also be used, particularly where the combination gives a synergistic effect, for example in terms of gelation
- 30 properties. An example is xanthan - locust bean gum combinations.

The advantage of gellan over other materials is that it can be administered as a fluid system but in the nasal cavity the system will gel, thereby providing a bioadhesive effect and holding the drug at the absorptive surface for an extended period of time.

5

The grade of gellan gum can be Gelrite or Kelcogel from Kelco Int, Ltd. or other similar grades from other manufacturers. The gellan can be prepared at a concentration of 0.1 w/v to 15% but a preferred range of concentrations is 0.2% to 1%.

10

For some of the polymer materials monovalent or divalent cations must be present in the composition for gelling to occur. Such polymer materials include gellan gum, welan, rhamsan and alginate.

- 15 Suitable cations include sodium, potassium, magnesium and calcium. The ionic concentration is chosen according to the degree of gelling required, and allowing for the effect that the ionised drug present may have on gelling. At a 0.2% gum concentration, the divalent ions, calcium and magnesium give maximum gel hardness and modulus at molar
- 20 concentrations approximately one fortieth (1/40) of those required with the monovalent ions, sodium and potassium. A finite concentration of each cation is required to induce gelation. For the nasal formulations of the invention the ionic strength is kept sufficiently low to obtain a low viscosity formulation but sufficiently high to ensure gelation once
- 25 administration into the nasal cavity where gelation will take place due to the presence of cations in the nasal liquid. The ionic strength for a 0.5% gellan gum can be in the range of 0.1mM - 50mM for monovalent cations with the preferred range being 1mM - 5mM and 0.1mM - 5mM for divalent cations with the preferred range being 0.15mM - 1mM. For
- 30 higher concentrations of gellan gum the ionic strengths should be lowered

accordingly.

In a liquid formulation, the polymeric material will typically be provided in a concentration of from 0.01% to 20%, preferably 0.05-10%, more preferably 0.1% - 5%. The compositions of the invention can also contain  
5 any other pharmacologically acceptable, non-toxic ingredients such as preservatives, antioxidants, flavourings, etc. Benzalkonium chloride may be used as a preservative. The ICAM-1 is used in concentrations in the formulation in the range of 0.01% to 20% w/v, more preferably 0.1% to  
10 10% w/v and most preferably 0.2% to 5% w/v.

The liquid formulations are administered using well-known nasal spray devices. If the formulations are freeze-dried, they can be administered using a nasal insufflator, as for the microsphere preparations.

15

It has been found that by administering ICAM-1 to the nasal cavity with the bioadhesive material according to the invention, the effectiveness of the ICAM-1 in the nasal cavity is greatly increased. It is thought that this is due to the delay in mucociliary clearance of the ICAM-1 from the nasal  
20 cavity which is caused by the bioadhesive material, and also the controlled release of the ICAM-1 from the bioadhesive material.

Preferred embodiments of the invention will now be illustrated in more detail by way of the following examples.

25

### Example 1

Into a 20ml volumetric flask weighed 100 mg of chitosan glutamate (Sea Cure +210). 5ml of water was added to the chitosan which was left to  
30 stir overnight.

Into a beaker was weighed 1.36g of potassium dihydrogen phosphate and 2.80g of sodium chloride. The salts were dissolved in 80ml of water, the solution adjusted to pH 5.7 using 2N NaOH solution and then made to 100ml with water. When the chitosan had dissolved, 5ml of the phosphate  
5 buffer solution was added.

A formulation containing 10mg/ml ICAM and 5ml/ml chitosan was prepared by diluting the solution of chitosan in phosphate buffer 1:1 with 20mg/ml ICAM solution.

10

### Example 2

Into a 3ml glass vial was weighed 10mg of gellan gum (Keleogel, Kelco Inc). To the glass vial was added 1.8ml of 11mg/ml ICAM solution,  
15 0.05ml of 4mg/ml benzalkonium chloride solution and 0.15ml of water.

A small magnetic stirrer bar was added to the vial, and the contents stirred at room temperature for 24 hours to disperse the gellan gum.

### 20 Example 3

Into a 250ml conical flask were weighed 500mg of "Eldexomer" starch microspheres obtained from Perstorp, Sweden.

25 To the conical flask containing the microspheres was added 31ml of water and 1.6ml of 12.5mg/ml ICAM solution.

The flask contents were gently mixed and then left to stand for 30 minutes.

30

The contents of the conical flask were frozen by immersing the flask into liquid nitrogen. The flask was swirled during freezing to obtain a homogeneous mixture.

- 5 The flask was transferred to a freeze drier and the contents lyophilised for 24 hours. The resulting product was a free flowing powder containing 1mg of ICAM/21mg of formulation.

#### Example 4

10

Into a 10ml volumetric flask was weighed 1.0g of gelatin which was dissolved in 5ml of water by warming to 35-40°C.

- 15 To the gelatin solution was added 1.8ml of 22mg/ml ICAM solution. The flask contents were made to volume with water.

Into a beaker was measured 90mg of 1 % of 1 % w/v Span 80 in soya oil. The beaker contents were warmed to 35-40°C on a hot-plate.

- 20 The warmed Span/soya oil mixture was removed from the hot-plate and was stirred at 1000 rpm using an overhead stirrer.

The 10ml of ICAM/gelatin mixture was added to the stirring oil and stirred at 1000 rpm for 2 minutes.

25

While stirring continued, the beaker containing the emulsion was cooled to 15°C by surrounding in ice. Dropwise, 100ml of acetone was added to the cooled, stirred emulsion.

- 30 The gelatin-ICAM microspheres were recovered by centrifugation, washed



with acetone and left to dry at room temperature.

The result was a free-flowing powder containing 1mg of ICAM/26mg of formulation. The mean diameter of the microspheres was measured, using  
5 laser diffraction, to be 50 $\mu$ m.

#### Example 5

500mg of medium viscosity chitosan glutamate was dissolved in 50ml of  
10 water. 26mg of ICAM was dissolved in the chitosan solution. The chitosan/ICAM solution was spray-dried using a Lab-Plant SD-04 spray-dryer (Lab-Plant, Huddersfield, UK). The drying temperature was set at 100°C. Microspheres of approximately 5 $\mu$ m diameter was formed.

#### 15 Example 6

1000mg of gelatin was dissolved in 50ml of water at 40°C. 52mg of ICAM was dissolved in the gelatin solution. The chitosan/ICAM solution was spray-dried using a Lab-Plant SD-04 spray-dryer (Lab-Plant.  
20 Huddersfield, UK). The drying temperature was set at 100°C. Microspheres of approximate 5 $\mu$ m size were formed.

#### Example 7

25 An aqueous solution was prepared containing 2.1mg/ml ICAM, 1.4mg/ml Mannitol and 0.7mg/ml PBS. The solution was spray-dried at 100°C to form microparticles of approximately 5 $\mu$ m size. 10mg of spray dried ICAM and 100mg of Eldexomer starch microspheres were weighed into a bottle and placed on to a roller mixer for 30 minutes. The resulting  
30 formulation consisted of starch microspheres coated with particles of

spray-dried ICAM.

## CLAIMS

1. A drug delivery composition for nasal administration comprising ICAM-1 and a bioadhesive material.

5

2. A drug delivery composition according to claim 1 wherein the bioadhesive material is a chitosan solution.

3. A drug delivery composition according to claim 2 wherein the  
10 chitosan is in the solution in a concentration in the range of 0.2 - 2.0% w/v.

4. A drug delivery composition according to claim 2 or 3 wherein the ICAM-1 is present in the chitosan solution in a concentration in the range  
15 0.2 to 5% w/v.

5. A drug delivery composition according to claim 1 wherein the bioadhesive material is a plurality of microspheres.

20 6. A drug delivery composition according to claim 5 wherein the microspheres are made from starch, chitosan, gelatin, hyaluronic acid, alginate or gellan.

7. A drug delivery composition according to claim 5 or 6 wherein the  
25 ICAM-1 is present in an amount of 1 % to 20% w/w of the microspheres.

8. A drug delivery composition according to claim 1 wherein the bioadhesive material is a liquid formulation comprising a polymeric material.

30

9. A drug delivery composition according to claim 8 wherein the polymeric material is gellan gum, alginate, welan, xanthan or rhamsan.
10. A drug delivery composition according to claim 8 or 9 wherein the  
5 polymeric material is provided in a concentration of 0.1% to 5% w/v.
11. A drug delivery composition according to any one of claims 8 to 10 wherein the ICAM-1 is present in the formulation in an amount of 0.2% to 5% w/v.
- 10
12. A method of delivering ICAM-1 to the nasal cavity to increase its effectiveness therein comprising administering the ICAM-1 in a drug delivery composition additionally comprising a bioadhesive material.

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/17 A61K9/00 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 06842 (BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.) 15 April 1993 see page 31, line 13 - page 35, line 10 see page 46, line 21 - page 47, line 10 ---	1-12
Y	EP,A,0 362 531 (MOLECULAR THERAPEUTICS INC.) 11 April 1990 see page 4, line 13 - line 22 see page 9, line 58 - page 10, line 9 ---	1-12
Y	WO,A,90 05522 (P. PRISELL ET AL.) 31 May 1990 see claims ---	1-12
A	EP,A,0 314 863 (BAYLOR COLLEGE OF MEDICINE) 10 May 1989 see page 8, line 45 - line 53 see page 9, line 18 - page 10, line 24 --- -/--	1-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 October 1995

Date of mailing of the international search report

16. 11. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Nooij, F

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NATURE, vol. 344, 1 March 1990 LONDON, GB, pages 70-72, S MARLIN ET AL. 'A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection.' cited in the application see abstract ---	1,12
A	WO,A,94 00485 (MILES INC.) 6 January 1994 see claims ---	1,12
A	WO,A,91 06282 (DANBIOSYST UK LTD.) 16 May 1991 cited in the application see the whole document ---	1,5-7,12
A	TRENDS IN BIOTECHNOLOGY, vol. 9, no. 8, August 1991 CAMBRIDGE, GB, pages 284-289, L. ILLUM 'The nasal delivery of peptides and proteins.' see page 285, left column, line 60 - right column, line 11 see page 288, right column, line 35 - line 60 ---	1,5-7,12
P,A	WO,A,94 27576 (DANBIOSYST UK LTD.) 8 December 1994 see examples see claims -----	1,5-12

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB95/01735

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 12 is directed to a method of treatment of the  
human/animal body, the search has been carried out and based on the  
alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such  
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9306842	15-04-93	AU-A- 2763692	03-05-93
EP-A-362531	11-04-90	AU-B- 637324	27-05-93
		AU-B- 4027189	08-03-90
		JP-A- 2238892	21-09-90
		PT-B- 91570	31-05-95
WO-A-9005522	31-05-90	AU-B- 632074	17-12-92
		AU-B- 4525389	12-06-90
		EP-A- 0444081	04-09-91
		JP-T- 5505169	05-08-93
		SE-A- 8804164	17-11-88
EP-A-314863	10-05-89	AT-T- 114972	15-12-94
		AU-B- 1550988	27-07-89
		AU-B- 2633388	27-07-89
		CA-A- 1331132	02-08-94
		DE-D- 3852374	19-01-95
		DE-T- 3852374	04-05-95
		ES-T- 2064327	01-02-95
		JP-A- 1135724	29-05-89
WO-A-9400485	06-01-94	AU-B- 4543293	24-01-94
		EP-A- 0604624	06-07-94
		FI-A- 946006	21-12-94
		JP-T- 6510208	17-11-94
		NO-A- 944966	21-12-94
WO-A-9106282	16-05-91	GB-A- 2237510	08-05-91
		EP-A- 0500594	02-09-92
		JP-T- 5501408	18-03-93
WO-A-9427576	08-12-94	AU-B- 6727294	20-12-94